Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by means of questionnaires completion and direct questioning.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Budesonide, Formoterol Fumarate Drug Combination

Criteria

Inclusion Criteria:

• Minimum of 6 months history of asthma and treatment with an inhaled corticosteroids for at least 3 months prior to visit 1 and/or a history of short term variation in airway function and asthma symptoms responding promptly to convent

• Patients where use of a combination (inhaled corticosteroid and long acting beta2-agonist is appropriate, i.e. not controlled on inhaled corticosteroids alone).

Exclusion Criteria:

• Asthma exacerbation requiring oral corticosteroid treatment in the four weeks prior to visit 1

• Upper Respiratory Tract Infection in the previous four weeks

• Severe cardiovascular disease or other significant concomitant disease, which may interfere with the conduct of the study.

• Women enrolled in the trial should not be planning pregnancy and should be taking adequate contraceptive measures where appropriate.

• Previous enrollment in a clinical study

• Known or suspected hypersensitivity to budesonide, formoterol or inhaled lactose